Class action lawsuit puts Hercules Capital’s processes under scrutiny

Hercules Capital (HTGC) is under fresh legal scrutiny after a new class action lawsuit tied to allegations about its deal sourcing, portfolio valuation practices, and classification of software related debt exposure.

The complaint, filed following a Hunterbrook Media report and a sharp single day share price drop in February 2026, raises questions around the company’s internal controls and past disclosures to investors.

At a share price of US$14.50, Hercules Capital has seen short term pressure, with a 30 day share price return of 6.0% decline and a 90 day share price return of 21.2% decline. However, the 3 year total shareholder return of 56.4% points to a much stronger longer term picture and suggests recent momentum has faded as legal and valuation concerns draw more attention.

If this legal scrutiny has you reassessing where risk sits in your portfolio, it can be useful to compare Hercules with other income focused lenders and financing names using a broader set of filters, including balance sheet strength and sector exposure. You can then widen your research with 20 top founder-led companies

With Hercules Capital trading at US$14.50 and sitting at a roughly 41% discount to one intrinsic estimate and about 37% below the average analyst target, the key question is simple: is this legal overhang creating a mispricing, or is the market correctly adjusting for future risks?

Most Popular Narrative: 28.6% Undervalued

With Hercules Capital’s fair value narrative sitting at about $20.31 against a last close of $14.50, the gap between price and modeled value is wide enough to make the underlying assumptions worth understanding.

Recent research on Hercules Capital has focused on fine tuning valuation rather than calling for a major shift in the story. Price targets have been adjusted by US$1, with analysts citing higher modeled discount rates and tweaks to assumed future P/E, while keeping their broader long term outlook largely intact.

Want to see what keeps that fair value steady even as discount rates edge higher? The core narrative leans on compounded revenue gains, resilient margins, and a future earnings multiple that still assumes investor confidence. Curious which specific growth and profitability paths have to hold up for that valuation gap to close?

Result: Fair Value of $20.31 (UNDERVALUED)

However, this depends on competition not compressing lending yields too far and on tech and life sciences avoiding a downturn that could hit credit quality.

Next Steps

With sentiment clearly mixed, and both legal risk and valuation upside in focus, now is the time to look through the numbers yourself and weigh the trade off between concern and optimism by checking the 4 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Hercules has you thinking harder about risk and reward, do not stop here. Broaden your watchlist with focused ideas that match your goals and comfort level.

• Target potential mispricings by scanning a focused list of companies screened as 55 high quality undervalued stocks.
• Prioritise reliable income by reviewing a curated set of high yield opportunities through the 12 dividend fortresses.
• Dial down risk by concentrating on companies identified in the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.